US 12,459,902 B2
Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile and formulations thereof
Michael Mutz, Freiburg im Breisgau (DE); Fang Wang, Shanghai (CN); and Mei Xia, Shanghai (CN)
Assigned to Bausch + Lomb Ireland Limited, Dublin (IE)
Appl. No. 18/040,552
Filed by Bausch + Lomb Ireland Limited, Dublin (IE)
PCT Filed Aug. 4, 2021, PCT No. PCT/IB2021/057165
§ 371(c)(1), (2) Date Feb. 3, 2023,
PCT Pub. No. WO2022/029656, PCT Pub. Date Feb. 10, 2022.
Claims priority of application No. PCT/CN2020/107444 (WO), filed on Aug. 6, 2020.
Prior Publication US 2023/0286924 A1, Sep. 14, 2023
Int. Cl. C07D 239/91 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/517 (2006.01)
CPC C07D 239/91 (2013.01) [A61K 9/0048 (2013.01); A61K 9/08 (2013.01); A61K 31/517 (2013.01); C07B 2200/13 (2013.01)] 20 Claims
 
1. A crystal form of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I) having structure

OG Complex Work Unit Chemistry
or a hydrate thereof,
wherein the crystal form is selected from form K′, form M, form HB, and form Q.